Stephen G Ellis

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:751-3. 2002
  2. doi request reprint 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:909-16. 2009
  3. ncbi request reprint Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
  4. doi request reprint Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiology, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:1248-59. 2009
  5. doi request reprint Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    JACC Cardiovasc Interv 1:227-32. 2008
  6. doi request reprint Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experience
    Olcay Aksoy
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:E1-8. 2013
  7. ncbi request reprint Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes
    Juhana Karha
    The Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:906-10. 2006
  8. ncbi request reprint Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
    Deepak P Vivekananthan
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 94:358-60. 2004
  9. pmc Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis
    Inder M Singh
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Catheter Cardiovasc Interv 76:257-62. 2010
  10. doi request reprint Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study
    Gus Theodos
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:294-300. 2013

Detail Information

Publications105 found, 100 shown here

  1. ncbi request reprint Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:751-3. 2002
  2. doi request reprint 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:909-16. 2009
    ..The aim of this report was to evaluate 12-month outcomes of facilitated percutaneous coronary intervention (PCI) in the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial...
  3. ncbi request reprint Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
    ....
  4. doi request reprint Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiology, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:1248-59. 2009
    ....
  5. doi request reprint Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    JACC Cardiovasc Interv 1:227-32. 2008
    ..We sought to examine the clinical outcomes of patients treated with drug-eluting stents (DES) compared with bare-metal stents (BMS) during primary angioplasty for ST-segment elevation myocardial infarction (STEMI)...
  6. doi request reprint Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experience
    Olcay Aksoy
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:E1-8. 2013
    ..To determine the role of percutaneous coronary intervention (PCI) and its impact on mortality in coronary artery disease (CAD)...
  7. ncbi request reprint Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes
    Juhana Karha
    The Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:906-10. 2006
    ..92, 95% confidence interval 0.69 to 1.23, p = 0.59). In conclusion, adjunctive use of platelet GP IIb/IIIa inhibitors in saphenous vein graft PCI does not appear to be associated with less myonecrosis or improved survival...
  8. ncbi request reprint Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
    Deepak P Vivekananthan
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 94:358-60. 2004
    ..Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model...
  9. pmc Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis
    Inder M Singh
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Catheter Cardiovasc Interv 76:257-62. 2010
    ..We compared the long-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) for treatment of bare-metal in-stent restenosis (ISR)...
  10. doi request reprint Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study
    Gus Theodos
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:294-300. 2013
    ..To investigate the safety and risk of vascular complications of arteriotomy closure devices (ACD) with the direct thrombin inhibitor bivalirudin in patients undergoing percutaneous coronary intervention (PCI)...
  11. ncbi request reprint Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
    ..Conversely, if the benefits of DESs are attenuated in routine practice, many groups of patients treated with BMSs may have nearly comparable results...
  12. doi request reprint Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting
    Bhuvnesh Aggarwal
    Department of Internal Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 62:409-15. 2013
    ..This study sought to ascertain causes of death and the incidence of percutaneous coronary intervention (PCI)-related mortality within 30 days...
  13. ncbi request reprint Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial
    Stephen G Ellis
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 147:E16. 2004
    ..We hypothesize that a strategy of early pharmacologic reperfusion therapy with abciximab alone or in conjunction with reduced-dose reteplase, followed by PCI will improve the outcome of patients eligible for primary PCI...
  14. doi request reprint Drug-eluting stent fracture and acute coronary syndrome
    Adnan K Chhatriwalla
    Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cardiovasc Revasc Med 10:166-71. 2009
    ..Coronary stent fracture is an underrecognized entity but has been reported more frequently in the drug-eluting stent (DES) era. Nevertheless, the clinical implications of coronary stent fracture remain unclear...
  15. ncbi request reprint In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 49:849-54. 2007
    ....
  16. doi request reprint Enhanced prediction of mortality after percutaneous coronary intervention by consideration of general and neurological indicators
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 4:442-8. 2011
    ..This study sought to improve methodology for predicting post-percutaneous coronary intervention (PCI) mortality...
  17. ncbi request reprint Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy--a propensity-adjusted analysis
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
    Am Heart J 151:1031.e1-6. 2006
    ..1% vs 52.3%, P < .001) or significant myonecrosis (7.5% vs 21.8%, P < .001) was significantly lower among patients pretreated with statins. This difference remained significant after multivariable and propensity adjustment...
  18. ncbi request reprint Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:616-8. 2006
    ..This finding was present in the BMS and SES groups and highlights the need for aggressive risk-factor modification after PCI...
  19. ncbi request reprint Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 92:1468-71. 2003
    ..3%, 7.5%, 8.1%, and 7.1%, respectively (p=0.71). The incidence of bleeding complications was 6.6%, 5.9%, 6.9%, and 7.3%, respectively (p=0.81). ACT did not independently predict either ischemic or hemorrhagic complications...
  20. ncbi request reprint Impact of female sex on outcome after percutaneous coronary intervention
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:998-1002. 2004
    ..Prior reports have suggested that women have increased mortality compared to men following percutaneous coronary intervention (PCI). It remains unclear if this difference is secondary to sex or other confounding variables...
  21. ncbi request reprint Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 40:1961-7. 2002
    ..The goal of this study was to assess the long-term impact of creatine kinase-MB isoform (CK-MB) elevation after percutaneous or surgical revascularization...
  22. ncbi request reprint Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction
    Allen Jeremias
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 143:1040-5. 2002
    ..Because CK-MB is frequently elevated in renal disease even in the absence of myocardial injury, the clinical significance of CK-MB elevation after PCI in patients with renal insufficiency has been questioned...
  23. ncbi request reprint GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention
    Jose E Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:1003-6. 2004
    ..We sought to analyze TMP after SVG-PCI with and without EPD and determine its impact on inhospital MACE...
  24. ncbi request reprint Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F 25, Cleveland, OH 44195 USA
    Eur Heart J 27:413-8. 2006
    ..The optimal revascularization strategy in patients with symptomatic multivessel coronary artery disease (CAD) and previous coronary artery bypass grafting (CABG) remains unknown...
  25. doi request reprint Influence of gender on long-term mortality in patients presenting with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention
    Dharam J Kumbhani
    Department of Cardiovascular Medicine, Cleveland Clinic, Ohio, USA
    Am J Cardiol 109:1087-91. 2012
    ..007). In conclusion, although overall mortality rates are similar between men and women undergoing PCI for NSTE-ACS, women <60 years old with negative biomarkers have a higher mortality than their men peers...
  26. ncbi request reprint Bare metal stent restenosis is not a benign clinical entity
    Michael S Chen
    The Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1260-4. 2006
    ..We hypothesized that a substantial proportion of bare metal ISR presents as acute coronary syndromes. We aimed to characterize the severity of the clinical presentation of ISR...
  27. ncbi request reprint Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shock
    Matthew A Cavender
    Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Invasive Cardiol 25:218-24. 2013
    ....
  28. pmc Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator
    Edwin T Zishiri
    Departments of Cardiovascular Medicine, Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Circ Arrhythm Electrophysiol 6:117-28. 2013
    ..We determined mortality risk in postrevascularization patients with left ventricular ejection fraction ≤35% and compared survival with those discharged with a wearable cardioverter defibrillator (WCD)...
  29. doi request reprint Drug-eluting versus bare-metal stents for treating saphenous vein grafts
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44114, USA
    Am Heart J 158:637-43. 2009
    ..Current data show conflicting results regarding safety and efficacy of drug-eluting stents (DES) versus bare-metal stents (BMS) for treating saphenous vein grafts (SVG). Our objective was to compare DES with BMS for SVG intervention...
  30. ncbi request reprint Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting
    Philippe L L'Allier
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
    Can J Cardiol 19:1041-6. 2003
    ..Most studies have demonstrated similar outcomes and a more favourable safety profile supporting this change in practice patterns...
  31. doi request reprint High-risk coronary atheroma: the interplay between ischemia, plaque burden, and disease progression
    Rishi Puri
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
    J Am Coll Cardiol 63:1134-40. 2014
    ..These observations, coupled with the efficacy of contemporary medical therapies in reducing clinical event rates, have important implications for trial design of future human in vivo evaluations of vulnerable coronary plaque...
  32. doi request reprint Facilitated PCI in patients with ST-elevation myocardial infarction
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, F25, 9500 Euclid Ave, Cleveland, OH 44195, USA
    N Engl J Med 358:2205-17. 2008
    ....
  33. doi request reprint Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195 0002, USA
    JACC Cardiovasc Interv 2:329-36. 2009
    ..Our aim was to assess the incidence of all-cause mortality in patients with anemia undergoing percutaneous coronary intervention (PCI) receiving drug-eluting stents (DES) or bare-metal stents (BMS)...
  34. doi request reprint Comparison of outcomes of unprotected left main versus multivessel coronary artery interventions
    Shikhar Agarwal
    Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 108:15-20. 2011
    ..In conclusion, there was comparable short-term and long-term mortality in the LMCA PCI and multivessel PCI groups. LMCA stenting did not appear to incur incremental risk compared to multivessel PCI...
  35. doi request reprint Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:1041-8. 2008
    ..Our purpose was to examine the incidence of all-cause mortality among drug-eluting stents (DES) and bare-metal stents (BMS) while adjusting for many confounding factors generally not considered in prior studies...
  36. doi request reprint Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:1075-80. 2008
    ..The short-term and long-term safety and efficacy of paclitaxel versus sirolimus-overlapping drug-eluting stents (DES) is unknown. We sought to examine the clinical consequences of overlapping sirolimus versus paclitaxel DES...
  37. doi request reprint Outcomes of cardiac catheterization and percutaneous coronary intervention for in-hospital ventricular tachycardia or fibrillation cardiac arrest
    Thomas J Helton
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 80:E9-14. 2012
    ....
  38. ncbi request reprint Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 40:669-75. 2002
    ..The goal of this study was to evaluate the mortality benefit of beta-blockers after successful percutaneous coronary intervention (PCI)...
  39. ncbi request reprint Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
    Allen Jeremias
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:1209-11. 2002
  40. ncbi request reprint Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy
    Arman Askari
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 43:1908-14. 2004
    ....
  41. ncbi request reprint Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 99:1087-9. 2007
    ..016), 7 polymorphisms in 5 genes were associated with SVG patency (p <0.01). In conclusion, these data represent an initial step toward the use of a personalized genetic approach to coronary revascularization...
  42. ncbi request reprint The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention
    Robert B Fathi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 150:1190-7. 2005
    ..We sought to assess the relationship among glomerular filtration rate (GFR), systemic inflammation, and long-term death after PCI...
  43. ncbi request reprint Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1043-51. 2007
    ..This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent...
  44. ncbi request reprint The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients
    David S Lee
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:46-51. 2004
    ....
  45. ncbi request reprint Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 105:691-6. 2002
    ..Therefore, we hypothesized that statin therapy has an early beneficial effect among patients undergoing PCI...
  46. doi request reprint Severe aortic stenosis and coronary artery disease--implications for management in the transcatheter aortic valve replacement era: a comprehensive review
    Sachin S Goel
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Am Coll Cardiol 62:1-10. 2013
    ..Ongoing studies randomizing patients to surgical or percutaneous management strategies for severe AS will help provide valuable data regarding the impact of CAD on TAVR outcomes, the role of PCI, and its timing in relation to TAVR. ..
  47. doi request reprint Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 101:169-72. 2008
    ..Diabetes mellitus and advanced co-morbidity were the principal determinants of survival. These findings support the need for randomized trials with adequate follow-up to compare the 2 approaches...
  48. ncbi request reprint Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention
    Brendan K Duffy
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:993-6. 2006
    ..46, 95% confidence interval 1.4 to 4.4, p = 0.002). In conclusion, an elevated preprocedural N/L ratio in patients undergoing PCI is associated with an increased risk of long-term mortality...
  49. ncbi request reprint Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:1051.e9-14. 2006
    ..Preclinical studies suggest that administration of cytokines to mobilize stem cells and alter the postinfarction inflammatory cardiac milieu may enhance left ventricular function and survival...
  50. ncbi request reprint Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Invasive Cardiol 19:404-9. 2007
    ..We sought to ascertain and compare 12-month target vessel revascularization (TVR) rates for sirolimus-eluting Cyphertrade mark stents and bare-metal stents (BMS) when utilized to treat stenoses in diseased SVGs...
  51. doi request reprint Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis
    Inder M Singh
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 75:338-42. 2010
    ..28) were also not different. This study represents the largest analysis comparing drug-eluting to bare-metal ISR. On multivariable Cox proportional hazard analyses, drug-eluting and bare-metal ISR have similar long term outcomes...
  52. ncbi request reprint Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era
    Niranjan Seshadri
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 106:2346-50. 2002
    ..We sought to determine the prevalence, indications, predictors, and complications of emergency CABG after PCI in the past decade...
  53. ncbi request reprint Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 106:1205-10. 2002
    ..Creatine kinase (CK)-MB elevation after percutaneous coronary intervention (PCI) has been associated with subsequent cardiac death. The patients at risk, the timing of risk, and potential treatment implications are uncertain...
  54. doi request reprint Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement
    Sachin S Goel
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, J2 3, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Circulation 125:1005-13. 2012
    ..Outcomes of percutaneous coronary intervention (PCI) in patients with severe AS and coronary artery disease remain unknown. We sought to compare the short-term outcomes of PCI in patients with and without AS...
  55. doi request reprint Influence of transcatheter aortic valve replacement strategy and valve design on stroke after transcatheter aortic valve replacement: a meta-analysis and systematic review of literature
    Ganesh Athappan
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio
    J Am Coll Cardiol 63:2101-10. 2014
    ..transapical [TA]) and valve designs (CoreValve, Medtronic, Minneapolis, Minnesota vs. Edwards Valve, Edwards Lifesciences, Irvine, California) for transcatheter aortic valve replacement (TAVR)...
  56. ncbi request reprint Outcomes in African Americans and whites after percutaneous coronary intervention
    Michael S Chen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Med 118:1019-25. 2005
    ..We aimed to determine whether African Americans and whites have different outcomes after percutaneous coronary intervention (PCI)...
  57. doi request reprint Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery
    Andrew N Rassi
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 110:485-90. 2012
    ..Clinicians who are considering this strategy must weigh the risks of stent thrombosis versus bleeding...
  58. ncbi request reprint Stent-assisted detachable coil embolization of pseudoaneurysms in the coronary circulation
    Anjli Maroo
    Department of Cardiovascular Medicine, Section of Interventional Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 68:409-15. 2006
    ....
  59. doi request reprint Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA
    Eur Heart J 29:1625-34. 2008
    ....
  60. ncbi request reprint Dynamic change in mitral annular area and motion during percutaneous mitral annuloplasty for ischemic mitral regurgitation: preliminary animal study with real-time 3-dimensional echocardiography
    Masao Daimon
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Soc Echocardiogr 20:381-8. 2007
    ..3 +/- 1.1-7.0 +/- 1.9 mm, P = .13). This 3D echocardiographic method noninvasively enabled dynamic study of mitral annular geometry and motion with quantitative analysis of the impact of PTMA...
  61. ncbi request reprint Relation of myocardial perfusion to mortality after primary percutaneous coronary intervention
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:980-2. 2005
    ..This observation has important implications for the methods of evaluating primary PCI results and the strategies used to improve myocardial reperfusion...
  62. ncbi request reprint Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 45:1193-200. 2005
    ..We sought to evaluate the relationship between angiographic late loss and clinical outcomes in the drug-eluting stent era...
  63. ncbi request reprint Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts
    Umesh N Khot
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 109:2086-91. 2004
    ..The radial artery has been increasingly used in CABG. However, angiographic outcome data have been limited...
  64. ncbi request reprint Preprocedural white blood cell count and death after percutaneous coronary intervention
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 146:692-8. 2003
    ..An elevation in the white blood cell (WBC) count is a nonspecific response to inflammation. We hypothesized that an elevated WBC count would be a predictor of death in patients undergoing PCI...
  65. ncbi request reprint Prevalence of conventional risk factors in patients with coronary heart disease
    Umesh N Khot
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    JAMA 290:898-904. 2003
    ..This claim implies that other factors play a significant role in CHD and has led to considerable interest in nontraditional risk factors and genetic causes of CHD...
  66. ncbi request reprint Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA
    Catheter Cardiovasc Interv 67:541-5. 2006
    ..Retroperitoneal hemorrhage (RPH) is an infrequent but occasionally fatal complication of percutaneous coronary intervention (PCI). Therefore, it has been studied in relatively small numbers of patients...
  67. ncbi request reprint Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival
    Fernando A Cura
    Department of Cardiology, Instituto Cardiovascular de Buenos Aires, Argentina
    Am J Cardiol 91:587-90. 2003
  68. ncbi request reprint Renal failure after percutaneous coronary intervention is associated with high mortality
    Ritesh Gupta
    Division of Cardiology, Department of Medicine, University of Alabama, Birmingham, USA
    Catheter Cardiovasc Interv 64:442-8. 2005
    ..6% +/- 0.27% in those without any post-PCI renal insufficiency (P < 0.0001). Acute renal insufficiency after PCI is a strong and independent predictor of long-term mortality in patients who survived for 30 days after the procedure...
  69. ncbi request reprint Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial)
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    Am J Cardiol 95:709-15. 2005
    ..Paclitaxel-eluting stents attenuate the increased risk associated with obesity, such that the intermediate-term prognosis after percutaneous coronary intervention is independent of weight...
  70. ncbi request reprint Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:315-8. 2002
  71. ncbi request reprint Effects of long-term prednisone (> or =5 mg) use on outcomes and complications of percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F 25, Cleveland, OH 44195, USA
    Am J Cardiol 93:1389-90, A6. 2004
    ..Steroid use was not associated with increased risk of composite major ischemia events but was associated with a threefold risk (p = 0.01) of major vascular complications and a three- to fourfold risk (p = 0.026) of coronary perforation...
  72. ncbi request reprint Incremental progress? The roles of direct stenting and routine troponin measurement after percutaneous coronary intervention
    Stephen G Ellis
    Sones Cardiac Catheterization Labs, The Cleveland Clinic Foundation, F25, One Clinic Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 14:171-2. 2002
  73. ncbi request reprint One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial
    Gregg W Stone
    The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022, USA
    Circulation 109:1942-7. 2004
    ..The safety and efficacy of the slow-release, polymer-based, paclitaxel-eluting stent after implantation in a broad cross section of de novo coronary lesions at 1 year are unknown...
  74. ncbi request reprint Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:9-14. 2002
    ..We sought to determine whether clopidogrel is at least as efficacious as ticlopidine...
  75. ncbi request reprint Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Circulation 106:3063-7. 2002
    ..Despite widespread use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors for percutaneous coronary interventions (PCI) of bypass grafts, data supporting this strategy are lacking...
  76. ncbi request reprint A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
    Gregg W Stone
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York 10022, USA
    N Engl J Med 350:221-31. 2004
    ..Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis...
  77. ncbi request reprint Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy
    Jacqueline E Tamis-Holland
    Division of Cardiology, St Luke s Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
    Am Heart J 147:133-9. 2004
    ..Direct angioplasty (PTCA) and thrombolytic therapy are the chief therapies for treating an ST-segment elevation myocardial infarction (MI)...
  78. ncbi request reprint Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists
    Wojciech Mazur
    Baylor College of Medicine and The Methodist Hospital, Houston, Tex, USA
    Am Heart J 143:594-601. 2002
    ..The purpose of this study was to compare the effects of abciximab in patients with and without high-risk postprocedure features...
  79. ncbi request reprint Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial
    Mitchell J Ross
    Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 42:981-8. 2003
    ..We sought to assess whether pre-procedural angiographic characteristics are associated with adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition...
  80. ncbi request reprint Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial)
    Jeffrey W Moses
    Lenox Hill Heart and Vascular Institute and Cardiovascular Research Foundation, New York, New York 10021, USA
    Am J Cardiol 90:243-7. 2002
    ..The relative impact of this treatment is more pronounced in diabetic patients because it appears to neutralize the added risk of recurrent restenosis seen in proliferative diabetic lesions...
  81. ncbi request reprint Periprocedural myonecrosis: from a laboratory anomaly to a sentinel of risk
    Hitinder S Gurm
    Ital Heart J 4:1-3. 2003
  82. ncbi request reprint Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition
    Leslie Cho
    Department of Cardiology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Am J Cardiol 91:742-3. 2003
  83. ncbi request reprint Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:132-6. 2002
    ....
  84. ncbi request reprint Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial
    James B Hermiller
    St Vincent s Hospital, Indianapolis, Indiana, USA
    J Am Coll Cardiol 45:1172-9. 2005
    ..We sought to determine the safety and efficacy of polymer-regulated site-specific delivery of paclitaxel in patients with diabetes mellitus undergoing stent implantation...
  85. doi request reprint Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials)
    Jiro Aoki
    Columbia University Medical Center, New York, New York, USA
    Am J Cardiol 102:1009-16. 2008
    ..In conclusion, neointimal proliferation was less prominent and expansive vessel remodeling was more prominent after PES than BMS implantation, independent of the severity of renal dysfunction...
  86. ncbi request reprint The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy
    Hitinder S Gurm
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48109 0311, USA
    J Invasive Cardiol 19:225-8. 2007
    ....
  87. ncbi request reprint Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial
    Amir Halkin
    Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 150:1163-70. 2005
    ..We sought to evaluate the impact of baseline RI on clinical and angiographic outcomes in patients undergoing elective percutaneous coronary intervention using either bare metal or paclitaxel-eluting stents...
  88. ncbi request reprint Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 295:1253-63. 2006
    ..The effectiveness of drug-eluting stents in this setting has not been established...
  89. ncbi request reprint Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial
    Jeffrey W Moses
    Columbia University Medical Center, New York, New York, USA
    J Am Coll Cardiol 45:1165-71. 2005
    ..We sought to investigate the outcomes of paclitaxel-eluting stent implantation in patients with unstable angina or non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI)...
  90. ncbi request reprint Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction
    J Emilio Exaire
    Instituto Nacional de Cardiologia, Mexico City, Mexico
    Arch Cardiol Mex 76:376-82. 2006
    ....
  91. ncbi request reprint Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 356:998-1008. 2007
    ..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data...
  92. ncbi request reprint Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial
    Giora Weisz
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10032, USA
    J Am Coll Cardiol 47:1350-5. 2006
    ..The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study...
  93. ncbi request reprint Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials
    Jeffrey W Moses
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 47:2164-71. 2006
    ....
  94. ncbi request reprint Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials
    Neil J Weissman
    Cardiac Ultrasound and Ultrasound Core Laboratory, Cardiovascular Research Institute Medstar Research Institute, Washington Hospital Center, 100 Irving Street, NW, Suite EB 5123, Washington, DC 20010, USA
    Eur Heart J 28:1574-82. 2007
    ..Since intravascular ultrasound (IVUS) methodology and core laboratory were consistent among all three TAXUS trials, an integrated analysis of 956 patients across all IVUS cohorts can be performed providing superior power...
  95. ncbi request reprint ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and
    Spencer B King
    Circulation 116:98-124. 2007
  96. ncbi request reprint "Crying fire in a theater" or a "confirmatory sighting?"
    Stephen G Ellis
    J Am Coll Cardiol 50:268-9. 2007
  97. ncbi request reprint Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease
    Alexandra J Lansky
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 45:1180-5. 2005
    ..We sought to determine whether gender influences the results of paclitaxel-eluting stent implantation...
  98. ncbi request reprint Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery
    George Dangas
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 45:1186-92. 2005
    ..We sought to examine the efficacy of paclitaxel-eluting stent implantation in the left anterior descending coronary artery (LAD)...
  99. ncbi request reprint Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial
    Neil J Weissman
    Washington Hospital Center, Washington, DC 20010, USA
    J Am Coll Cardiol 45:1201-5. 2005
    ..The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitaxel-eluting stents on in-stent neointima formation and late incomplete stent apposition...
  100. doi request reprint Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus
    Masashi Kimura
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 101:1263-8. 2008
    ....
  101. doi request reprint Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials
    Ajay J Kirtane
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 51:708-15. 2008
    ..We sought to examine the safety and efficacy of paclitaxel-eluting stents (PES) in patients with diabetes mellitus (DM)...